ESMOLOL SULFATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H25NO4.H2O4S
Molecular Weight	393.452
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1

InChI

InChIKey=KHCMVWJHIZXEKF-UHFFFAOYSA-N

InChI=1S/C16H25NO4.H2O4S/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;1-5(2,3)4/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H25NO4
Molecular Weight	295.374
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00187
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf

Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. Esmolol predominantly blocks the beta-1 receptors in cardiac tissue. Used for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 163 Target ID: CHEMBL213 Sources: http://www.drugbank.ca/drugs/DB00187	Antagonist 2849
sodium ion transport 14 Target ID: GO:0006814 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17235414	Inhibitor 8504		74.2 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Supraventricular tachycardia 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf	Primary		Approved 8583	BREVIBLOC Approved Use BREVIBLOC is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia Control of perioperative tachycardia and hypertension Launch Date 1986
Noncompensatory sinus tachycardia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf	Primary		Approved 8583	BREVIBLOC Approved Use BREVIBLOC is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia Control of perioperative tachycardia and hypertension Launch Date 1986

C_max

Value	Dose	Analyte	Population
0.22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.56 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.96 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1.5 mg single, intravenous dose: 1.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.02 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.03 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.06 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1.5 mg single, intravenous dose: 1.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.65 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.77 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.76 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28091703	1.5 mg single, intravenous dose: 1.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ESMOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf			ESMOLOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 ug/kg/min single, intravenous Dose: 400 ug/kg/min Route: intravenous Route: single Dose: 400 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/24687543/	unhealthy, 15 years Health Status: unhealthy Age Group: 15 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/24687543/	Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24687543/
500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	Other AEs: Hypotension asymptomatic, Hypotension symptomatic... Other AEs: Hypotension asymptomatic (25%) Hypotension symptomatic (12%) Infusion site reactions (8%) Nausea (7%) Dizziness (3%) Somnolence (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/1358003/	unhealthy, mean 44 years Health Status: unhealthy Age Group: mean 44 years Sources: https://pubmed.ncbi.nlm.nih.gov/1358003/	Sources: https://pubmed.ncbi.nlm.nih.gov/1358003/
500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/27523955/	unhealthy, mean 58 years Health Status: unhealthy Age Group: mean 58 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27523955/	Sources: https://pubmed.ncbi.nlm.nih.gov/27523955/

AEs

AE	Significance	Dose	Population
Delirium	1 patient Disc. AE	400 ug/kg/min single, intravenous Dose: 400 ug/kg/min Route: intravenous Route: single Dose: 400 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/24687543/	unhealthy, 15 years Health Status: unhealthy Age Group: 15 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/24687543/
Hypotension symptomatic	12%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
Hypotension asymptomatic	25%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
Dizziness	3%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
Somnolence	3%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
Nausea	7%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf
Infusion site reactions	8%	500 ug/kg single, intravenous Recommended Dose: 500 ug/kg Route: intravenous Route: single Dose: 500 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY572840	https://www.001chemical.com/chem/81147-92-4
abcr GmbH	AB505801	http://www.abcr.com/shop/en/AB505801
AHH Chemical co.,ltd	MT-50834	http://www.ahhchemical.com/product/MT-50834.html
AK Scientific, Inc. (AKSCI)	K444	http://www.aksci.com/item_detail.php?cat=K444
Angene	AGN-PC-0WH7EC	http://www.angenechemical.com/productshow/AGN-PC-0WH7EC.html
AvaChem Scientific	1690B	http://www.avachem.com/productSearch.asp?1690B
ChemMol	30101870	http://www.chemmol.com/chemmol/30101870.html
ChemMol	49421725	http://www.chemmol.com/chemmol/49421725.html
ChemMol	49422815	http://www.chemmol.com/chemmol/49422815.html
ChemMol	99171669	http://www.chemmol.com/chemmol/99171669.html
Clearsynth	CS-BV-00039	https://www.clearsynth.com/en/CSBV00039.html
DC Chemicals	DC36783	http://www.dcchemicals.com//product_show-Esmolol.html
Debye Scientific	DB-015362	http://www.debyesci.com/cas_103598-03-4.html
Finetech	FT-0630886	http://www.finetechnology-ind.com/prod/detail/pub/81147-92-4.html
Glentham Life Sciences	GP0641	http://www.glentham.com/products/product/GP0641/
Hairui	HR123893	http://www.hairuichem.com/en/product/81147-92-4.html
Molcore	MC572840	https://www.molcore.com/product/81147-92-4
OChem	9337	http://www.ocheminc.com/index.php?act=psearch&pid=147E924
Parchem	28880	http://www.parchem.com/chemical-supplier-distributor/Esmolol-018880.aspx
Parchem	87652	https://www.parchem.com/chemical-supplier-distributor/Esmolol-087652.aspx
Smolecule	S527432	http://www.smolecule.com/products/s527432
TCI (Tokyo Chemical Industry)	E1106	http://www.tcichemicals.com/eshop/en/us/commodity/E1106/index.html
THE BioTek	bt-267747	https://www.thebiotek.com/product/inhibitors/bt-267747
TripleBond	CE0048	http://www.triplebond-canada.com/prod/1304/
Yuhao Chemical	LT5536	http://www.chemyuhao.com/103598-03-4.html

PubMed

Title	Date	PubMed
Administration of esmolol in microlaryngeal surgery for blunting the hemodynamic response during laryngoscopy and tracheal intubation in cigarette smokers.	2007-02	17388233
The effect of intermittent low speed mode upon aortic valve opening in calves supported with a Jarvik 2000 axial flow device.	2005-04-21	15839437
[Intermittent complete left bundle branch block during general anesthesia].	2004-12	15682804
[Successful control of rapid heart rate with atrial flutter by intravenous administration of esmolol in a patient after total correction of the tetralogy of Fallot].	2004-08	15446684
The use of multi-frequency EPR techniques to identify the radicals produced in irradiated beta-blockers.	2004-01	15061654
Determination of radical yields in solid-state drugs as one technique to identify drugs that will withstand radiosterilization: radioresistance of beta blockers.	2003-07	12816529

Patents

Sample Use Guides

In Vivo Use Guide

Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia Optional loading dose: 500 mcg per kg infused over one minute Then 50 mcg per kg per minute for the next 4 minutes Adjust dose as needed to a maximum of 200 mcg per kg per minute Additional loading doses may be administered

Route of Administration: Intravenous

In Vitro Use Guide

In unpaced Langendorff-perfused rat hearts, esmolol (0.03-3 mmol/L) had a profound negative inotropic effect resulting in diastolic arrest at 1 mmol/L and above.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:04:03 GMT 2025` Edited by `admin` on `Mon Mar 31 21:04:03 GMT 2025`
Record UNII	4FAM116LV3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENZENEPROPANOIC ACID, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-, METHYL ESTER, SULFATE (2:1) (SALT)

Preferred Name

English

ESMOLOL SULFATE

Common Name

English

Code System Code Type Description

FDA UNII

4FAM116LV3

Created by admin on Mon Mar 31 21:04:03 GMT 2025 , Edited by admin on Mon Mar 31 21:04:03 GMT 2025

PRIMARY

CAS

81147-93-5

Created by admin on Mon Mar 31 21:04:03 GMT 2025 , Edited by admin on Mon Mar 31 21:04:03 GMT 2025

PRIMARY

PUBCHEM

126961356

Created by admin on Mon Mar 31 21:04:03 GMT 2025 , Edited by admin on Mon Mar 31 21:04:03 GMT 2025

PRIMARY

Related Record Type Details


					MDY902UXSR

ESMOLOL

PARENT -> SALT/SOLVATE

Related Record Type Details


					MDY902UXSR

ESMOLOL

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00187Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00187
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf

C_max

T_1/2

F_unbound